NEW YORK, Nov. 9, 2017 /PRNewswire/ -- If you want a Stock Review on IMGN, INCY, INFI, or INSM then come over to http://dailystocktracker.com/register/and sign up for your free customized report. Ahead of today's trading session, DailyStockTracker.com scans ImmunoGen Inc. (NASDAQ: IMGN), Incyte Corp. (NASDAQ: INCY), Infinity Pharmaceuticals Inc. (NASDAQ: INFI), and Insmed Inc. (NASDAQ: INSM). Biotech
On Wednesday, shares in Waltham, Massachusetts headquartered ImmunoGen Inc. climbed 0.90%, ending the day at $5.59. The stock recorded a trading volume of 1.72 million shares. The Company's shares have advanced 3.14% over the previous three months and 174.02% since the start of this year. The stock is trading above its 200-day moving average by 9.90%. Moreover, shares of ImmunoGen, which develops targeted anticancer therapeutics, have a Relative Strength Index (RSI) of 43.98.
On November 01st, 2017, ImmunoGen announced that three abstracts highlighting two of the Company's experimental ADC therapies, IMGN632 and IMGN779, have been accepted for presentations at the upcoming American Society of Hematology Annual Meeting to be held from December 09th, 2017, to December 12th, 2017 in San Diego. Both IMGN779 and IMGN632 use the Company's novel indolino-benzodiazepine payloads called IGNs, which alkylate DNA without crosslinking. IMGN complete research report is just a click away at:
Shares in Wilmington, Delaware headquartered Incyte Corp. ended the day 2.92% lower at $104.98 with a total trading volume of 1.37 million shares. The stock has gained 4.70% on an YTD basis, and is trading below its 50-day moving average by 10.54%. Shares of the Company, which focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology in the US and internationally, have an RSI of 31.86.
On October 30th, 2017, Incyte announced the appointment of Jacqualyn "Jackie" A. Fouse, Ph.D. as a new member of the Board of Directors, effective November 14th, 2017. Dr. Fouse is currently the Executive Chair of Dermavant Sciences, a position she has held since July 2017. Prior to joining Dermavant, she served in various senior capacities at Celgene Corporation, most recently as Strategic Advisor to the Management Executive Committee. The complimentary report on INCY can be downloaded at:
At the close of trading on Wednesday, shares in Cambridge, Massachusetts headquartered Infinity Pharmaceuticals Inc. finished 3.28% higher at $2.52 with a total trading volume of 833,233 shares. The stock has surged 72.60% in the last one month, 115.38% over the previous three months, and 86.67% on an YTD basis. The Company's shares are trading above their 50-day and 200-day moving averages by 47.79% and 30.37%, respectively. Additionally, shares of Infinity Pharma, which develops medicines for patients with difficult-to-treat diseases in the US, have an RSI of 58.39.
On October 12th, 2017, research firm Wells Fargo upgraded the Company's stock rating from 'Market Perform' to 'Outperform'.
On November 06th, 2017, Infinity Pharma announced that it will host a reception for investors and analysts on November 10th, 2017, from 6:00 a.m. to 8:00 a.m. to discuss the clinical development of IPI-549, including a review of data from the ongoing Phase-1/1b clinical study. The reception will take place in conjunction with the 2017 Society for Immunotherapy of Cancer Annual Meeting at the Gaylord National Hotel and Convention Center in National Harbor, MD. Sign up for your complimentary research report on INFI at:
Bridgewater, New Jersey headquartered Insmed Inc.'s shares recorded a trading volume of 652,771 shares at the end of yesterday's session. The stock closed the day flat at $30.15. The Company's shares have advanced 1.62% in the past month, 156.60% in the previous three months, and 127.89% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 9.60% and 59.23%, respectively. Additionally, shares of Insmed, which focuses on the development and commercialization of therapies for patients with rare diseases, have an RSI of 61.77.
On November 02nd, 2017, Insmed reported financial results for Q3 ended September 30th, 2017. Net loss for Q3 2017 was $45.2 million; R&D expenses were $26.7 million; and G&A expenses were $17.4 million. As of September 30th, 2017, the Company had cash and cash equivalents of approximately $431 million. Get free access to your research report on INSM at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.orgPhone number: (207)331-3313Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/technical-reports-on-biotech-equities----immunogen-incyte-infinity-pharma-and-insmed-300552723.html
Subscribe to our Free Newsletters!
Donating blood is a life-saving act. Consider increasing your iron intake before and after you ...
Exfoliative dermatitis or erythroderma is a skin condition where the skin becomes reddened and ...
Alström syndrome, a rare genetic disorder due to ALMS1 mutations, occurs in the first year of ...View All